中枢神经系统瘤中的Sirtuins-分子机制和治疗向
Agnieszka Nowacka1, Martyna Śniegocka2, Maciej Śniegocki1
1Department of Neurosurgery, Collegium Medicum in Bydgoszcz, Nicolas Copernicus University in Toruń, ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, Poland.
Cells
|July 25, 2025
概括
赛尔图因 (SIRT) 通过促进或抑制瘤对质瘤产生影响. 向这些酶的调节器对新型质瘤疗法和患者分层有前途.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生化学
背景情况:
- 赛尔图因 (SIRT) 是NAD+依赖的酶,参与关键的细胞过程.
- 它们在表观遗传调节,新陈代谢,DNA修复和应激反应中的作用与质瘤生物学有关.
研究的目的:
- 系统地审查SIRT1-SIRT7在中枢神经系统瘤中的分子机制和特定背景功能的研究,重点研究质瘤.
- 探索Sirtuin调节器在质瘤治疗中的治疗潜力.
主要方法:
- 对中枢神经系统瘤中sirtuins的文献进行系统审查.
- 对Sirtuin调节剂的临床前研究及其对质瘤细胞的影响的分析.
主要成果:
- SIRT1,SIRT3,SIRT5和SIRT7经常过度表达,促进质瘤的进展.
- 一般来说,SIRT2,SIRT4和SIRT6都是瘤抑制剂.
- 赛尔图因调节剂影响瘤生长,化学抵抗和关键信号通路 (例如,JAK2/STAT3,NF-κB).
结论:
- 赛尔图因是质瘤的有希望的治疗点.
- 对于组合策略和患者分层,需要对Sirtuin调节剂进行进一步的临床评估.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K


